There's no sugarcoating it: Biotech stocks have had a rough run in the past month.
But when other investors are running for the hills, Money Morning experts are finding profit plays. With biotech stocks trading lower, there are excellent buy-in opportunities on valuable biotech companies.
Orphan drugs offer some of the best profit plays in biotech as the have extremely lucrative markets cornered.
And these three stocks to buy are the best orphan drug plays now...
There's no sugarcoating it: Biotech stocks have had a rough run in the past month.
But when other investors are running for the hills, Money Morning experts are finding profit plays. With biotech stocks trading lower, there are excellent buy-in opportunities on valuable biotech companies.
Orphan drugs offer some of the best profit plays in biotech as the have extremely lucrative markets cornered.
And these three stocks to buy are the best orphan drug plays now...
Drugs that treat rare diseases - "orphan drugs" - can command breathtaking prices. Five approved by the Food and Drug Administration this year cost $150,000 per person, and three cost more than $300,000. That has helped triple global revenue for orphan drugs from $28 billion in 2004 to $84 billion last year. And over the next few years the biggest winners in this lucrative market are not going to be Big Pharma,
